Live Breaking News & Updates on Atxs

Stay updated with breaking news from Atxs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Astria Therapeutics (NASDAQ:ATXS) Trading Down 2.9% on Analyst Downgrade

Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report)’s stock price dropped 2.9% during trading on Tuesday after HC Wainwright lowered their price target on the stock from $18.00 to $16.00. HC Wainwright currently has a buy rating on the stock. Astria Therapeutics traded as low as $9.51 and last traded at $9.52. Approximately 312,375 shares […] ....

United States , Christopher Morabito , Jefferies Financial Group , Panagora Asset Management Inc , Astria Therapeutics Inc , Jump Financial , Astria Therapeutics Company Profile , Capital Management , Perceptive Advisors Llc , Astria Therapeutics , Get Free Report , Financial Group , Director Perceptive Advisors Llc , Asset Management , Astria Therapeutics Daily , Nasdaq Atxs ,

Astria Therapeutics (NASDAQ:ATXS) Hits New 12-Month High at $16.90

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) reached a new 52-week high on Monday . The stock traded as high as $16.90 and last traded at $14.89, with a volume of 1263985 shares trading hands. The stock had previously closed at $15.13. Wall Street Analyst Weigh In ATXS has been the subject […] ....

United States , Christopher Morabito , Astria Therapeutics Inc , Securities Exchange Commission , Perceptive Advisors Llc , Group Plc , Tower Research Capital , Astria Therapeutics , Get Free Report , Therapeutics Stock Down , Exchange Commission , Director Perceptive Advisors Llc , Research Capital , General Group Plc , California State Teachers Retirement System , Astria Therapeutics Daily , Nasdaq Atxs ,

Astria Therapeutics (NASDAQ:ATXS) Reaches New 12-Month High at $16.90

Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $16.90 and last traded at $14.89, with a volume of 1263985 shares traded. The stock had previously closed at $15.13. Wall Street Analysts Forecast Growth A number of research firms […] ....

United States , Christopher Morabito , Astria Therapeutics Inc , Vanguard Group Inc , Perceptive Advisors Llc , Perceptive Advisors , Blackrock Inc , Armistice Capital , Vivo Capital , Astria Therapeutics , Get Free Report , Therapeutics Trading Down , Director Perceptive Advisors Llc , Astria Therapeutics Daily , Nasdaq Atxs ,

Astria Therapeutics' (ATXS) Buy Rating Reaffirmed at HC Wainwright

Astria Therapeutics (NASDAQ:ATXS – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $18.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 20.16% from the company’s […] ....

United States , Christopher Morabito , Renaissance Technologies , Tower Research Capital , Securities Exchange Commission , Astria Therapeutics Company Profile , Perceptive Advisors Llc , Group Plc , Astria Therapeutics Inc , Astria Therapeutics , Get Free Report , Director Perceptive Advisors Llc , Exchange Commission , Research Capital , General Group Plc , Astria Therapeutics Daily , Nasdaq Atxs , Reiterated Rating , Hc Wainwright ,